San Francisco, 24 December 2018, Polycystic
Ovarian Syndrome (PCOS) Treatment Market Analysis By Drugs (Oral
Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants,
Anti-obesity), By Surgery, And Segment Forecasts, 2018 - 2025
The global polycystic ovarian syndrome treatment market is expected to reach USD 5.1 billion by 2025,
according to a new report by Grand View Research, Inc. According to the Centers
of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is
the most common cause of female infertility. Approximately 6% to 12% women of
reproductive age suffer from PCOS in the U. S. Moreover, progression of this
condition can lead to metabolic abnormalities, which may result in development
of type 2 diabetes, if the syndrome is not treated on time. The severity of the
disorder increases the risk of developing uterine and endometrial cancers in
patients. Thus, early diagnosis and effective treatment are significant for
successful recovery.
Presently, no specific drug is
commercially available for this condition. Thus, treating symptoms is the prime
aim of the treatment regimen. Owing to the various symptoms associated with
this syndrome, a range of drug class/combinations is used in the treatment.
Therefore, market leaders are focusing on developing a specific drug/treatment
to cure the root cause of this disease. AstraZeneca is one of the leaders
involved in developing such a drug.
Access Full Research
Report On Polycystic Ovarian Syndrome (PCOS)
Treatment Market Analysis:
Further Key Findings from the Study Suggest:
·
Constantly rising prevalence of
PCOS is primarily driving the growth of this market across the globe
·
Initiatives undertaken by
government bodies and market players to create awareness about benefits of
early diagnosis and commercially available treatment for PCOS among women is
boosting the market
·
Treatment of PCOS mainly
includes lifestyle modification through balanced diet, exercise, and drugs such
as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity
agents, and antidepressants
·
Surgical procedures such as
ovarian wedge resection and laparoscopic ovarian drilling are preferred when
patients do not respond to drug therapy
·
Insulin-sensitizing agents
segment is dominating the market since these drugs are widely used for
treatment of insulin resistance to prevent diabetes, which is a risk associated
with PCOS
·
Oral Contraceptive Pills (OCPs)
segment is expected to grow at the fastest rate followed by antiandrogen agents
that are used for treating symptomatic conditions such as hirsutism and acne
·
North America is dominating the
market followed by Europe. High awareness and availability of advanced
healthcare facilities are factors responsible for the dominant share held by
this region
·
Asia Pacific is expected to be
the fastest growing region over the forecast period.Increasing government
initiatives for raising awareness about symptoms & diagnosis of PCOS and
available treatment are increasing the number of women being diagnosed with
this syndrome in the region
·
China is one of the most
lucrative markets with tremendous growth opportunities for global as well as
local players owing to presence of a large pool of obese female population,
which is at high risk of PCOS
·
Key players in the market
include AstraZeneca, Bayer AG, Merck KGaA, Abbott, Sanofi, Pfizer, Inc.,
Bristol-Myer Squibb Company, and Novartis AG. The market also includes other emerging
players such as Teva Pharmaceutical Industries Limited and Ferring
Pharmaceuticals, Inc., which are expected to grow significantly in the near
future.
Browse More Reports Of This Category By
Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the PCOS
treatment market on the basis of drug class, surgery type, and region:
Drug Class Outlook (Revenue,
USD Billion; 2014 - 2025)
·
Oral Contraceptives
·
Antiandrogens
·
Insulin Sensitizing Agent
·
Antidepressant
·
Anti-obesity
Surgery Outlook (Revenue, USD
Billion; 2014 - 2025)
·
Ovarian Wedge Resection
·
Laparoscopic Ovarian Drilling
Regional Outlook (Revenue, USD
Billion; 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Mexico
o
Brazil
·
MEA
o
South Africa
Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-polycystic-ovarian-syndrome-pcos-treatment-market
www.grandviewresearch.com/press-release/global-polycystic-ovarian-syndrome-pcos-treatment-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information: www.grandviewresearch.com/
